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Coronary artery aneurysm (CAA) formation in the setting of an acute inﬂammatory state due to connective tissue disease is rare.
We report a case of rapid progression from an ectatic to an aneursymatic left circumﬂex coronary artery leading to an acute
coronaryevent in a patient with rheumatoid arthritis (RA).We report the accelerated growth ofthe aneurysm as itwas temporally
related to the lapse in treatment and the managementstrategies involved with this entity.
1.Introduction
Coronary artery aneurysm (CAA) formation in the setting
of systemic inﬂammatory conditions has been described.
We report a unique case of rapid development from ectasia
to aneurysm of the left circumﬂex coronary artery after
a lapse in treatment for rheumatoid arthritis (RA), which
wascomplicatedbyanon-STelevationmyocardialinfarction
( N S T E M I ) .W ed e s c r i b eo u rm a n a g e m e n ts t r a t e g ya n da l s o
discuss other systemic immune-inﬂammatory conditions
that have been associated with CAAs.
2.Case
A 67-year-old Caucasian man with a past medical history of
severeseropositiveRA,hypertension, coronary artery disease
(CAD)with previous stents, and ectasia of all three coronary
arteries presented with chest pain, nausea, and diaphoresis
that has been ongoing for the past 3-4 days. He reported
self-discontinuation of immunosuppressive therapy for RA
approximately four months ago, and subsequently he has
been experiencing pain in multiple joints and was found
to have elevated inﬂammatory markers (rheumatoid factor).
Upon further workup, he was found to have severe active
synovitis of the left wrist and left knee. The outpatient med-
ications included aspirin, clopidogrel, and warfarin which
were prescribedtopreventthrombusformationintheectatic
coronaries. However, due to poor adherence to this medical
therapy, the admission international normalized ratio (INR)
was found to be subtherapeutic.Elevated cardiac biomarkers
and electrocardiographic (ECG) changes (ST depression in
leads V5-V6) were consistent with an NSTEMI, and it was
decidedto proceedwith coronary angiography. Thisrevealed
a large, 23 millimeter mid-left circumﬂex coronary artery
aneurysm complicated by subtotal thrombosis with distal
run-oﬀ occlusion (Figure 1). The diﬀuse coronary artery
ectasia in the other coronary arteries appeared to be stable.
The aneurysm was determined to be rapidly enlarging, as
this was not present on a previous coronary angiogram six
months prior (Figure 2). A left ventriculogram revealed an
ejection fraction of 40%.
Attempts to cross the aneurysm to the distal artery
with multiple wires and catheters were unsuccessful due to
extensive clot burden in the aneurysm. After consulting with
the cardiac surgeons, it was decided to proceed with coil
embolization of this aneurysm to prevent clot propagation
and potential rupture in the future. A 7 French Cordis XB4
guiding catheter (Cordis Corp., Bridgewater, NJ) was used
to engage the left circumﬂex coronary artery. A 0.014 inch
J-tip guidewire was used to position a 0.018 inch inner
diameter microcatheter to deliver one 6-Nester (Cook Med-
ical, Bloomington, IN) and one 2–6 Tornado coil occluders2 Cardiology Research and Practice
Figure 1: Subtotal thrombus occlusion of the left circumﬂex coro-
nary artery aneurysm withblood ﬂowinto the aneurysm(arrow).
Figure 2: Angiogram six months prior reveals a mildly ectatic but
not aneurysmatic left circumﬂex coronary artery (arrow).
(Cook Medical) into the aﬀerent limb of the aneurysm.
Postdeploymentimages demonstrated complete occlusionof
the aneurysm (Figure 3). The patient reported mild chest
pain during the procedure which resolved spontaneously,
and postprocedure cardiac enzymes were down-trending
compared to initial values. Based on clinical, laboratory, and
angiographic data, it was postulated that the patient may
have experienced RA-induced coronary vasculitis leading to
aneurysm formation therefore, the patient was initiated on
immunosuppressive therapy (prednisone and methotrexate)
for RA. He was discharged home within 48 hours and at
1-year clinical followup, the patient reports no symptoms
and has excellent functional capacity with a left ventricular
ejection fraction of 50% with no wall motion abnormalities.
3.Discussion
Although the vast majority of acute coronary events result
from atherosclerotic lesions in coronary arteries, some cases
Figure 3: Successful coiling with no blood ﬂow into the aneurysm
(arrow).
of myocardial infarction are related to nonatherosclerotic
processes, such as coronary embolism, vasospasm, dissec-
tion, congenital abnormalitie s ,a n d ,i no u rc a s e ,a n e u r y s m .
CAAs are rare but potentially fatal if it is not managed
in a judicious and timely manner. The ﬁrst pathologic
description of a CAA was made by Morgagni in 1761 [1].
Munker and colleagues diagnosed this by angiography in
1958 [2] .T h ew i d er a n g ei nt h er e p o r t e di n c i d e n c e( 0 . 1 5 %
to 4.9%) is attributed to the conceptual diﬀerences in the
deﬁnition of coronary ectasia and aneurysm [1, 2]. CAA
is deﬁned as a segmental dilatation of the vessel, with a
diameter ≥1.5 times (some authors have deﬁned it as ≥2
times) of an adjacent normal section. Left main coronary
artery aneurysm is deﬁned as segmental dilatation ≥1.5
times the diameter of the widest normal coronary artery.
Ectasia is characterized bya more diﬀuse dilatation involving
at least 50% of the vessel length. Coronary ectasia and
aneurysm are thought to represent subsequent stages of a
dilatative process [3].
There are many inﬂammatory disorders, connective
tissue disorders, and infectious etiologies that have been
associated with CAAs. Atherosclerosis is the most common
etiology in the U.S., and Kawasaki’s disease is the most
common etiology in the Far East [4]. The pathophysiology
of the inﬂammatory conditions involve coronary vasculitis,
which causes thickening of the arteries leading to their
occlusion, and in some cases, weakening of the medial
layer of the vessel wall, leading to aneurysms. CAAs have
a male predominance and can be focal or diﬀuse in nature,
and classiﬁed morphologically as saccular or fusiform. The
most common location of CAAs, in order of decreasing
frequency, are the right coronary artery (40–87%), left
anterior descending artery, left circumﬂex artery, and then
rarely the left main coronary artery [5].
Coronary artery aneurysm associated with RA is rare
but has been described [6]. RA is a systemic inﬂamma-
tory disease characterized by chronic and erosive synovitis
that involves peripheral joints. A variety of extra-articularCardiology Research and Practice 3
manifestations have been described in RA and include sub-
cutaneous nodules, episcleritis, mononeuritis multiplex, se-
rositis, petechiae, and skin ulcers. Moreover, RA has been
associated with cardiovascular manifestations which include
pericarditis, cardiomyopathy, cardiac amyloidosis, coronary
vasculitis, arrhythmia, valvulopathy, congestive heart failure,
and ischemic heart disease. Systemic vasculitis complicating
RA has a reported mortality rate of up to 30% [7]. RA-
induced vasculitis has been implicated in causing aneurysms
of the aorta and other vascular beds, that is, the renal, ver-
tebral, spinal, hepatic, and coronary vasculature. Moreover,
the proinﬂammatory state of RA can also lead to accelerated
atherosclerosis, and it is a well-known independent risk
factor for multivessel CAD accounting for the increased
prevalence of coronary heart disease in this group of patients
[8]. However, the challenge for proponents of the “coronary
vasculitis” theory is clinically determining the etiology of
coronary changes (ectasia, aneurysms) as being primarily
due to vasculitis or atherosclerosis or the combination
of both. RA involvement in CAAs is primarily a clinical
diagnosis, as the deﬁnitive diagnosis is usually established at
autopsy.
Overall, most patients with CAAs are asymptomatic;
however,symptomsrelatedtothrombusformationwithsub-
sequent distal coronary thromboembolism, extrinsic native
vessel compression, ﬁstula formation, coronary spasm, or
even rupture can occur. Medical, interventional and sur-
gical strategies to manage coronary aneurysms have been
described. Preventative therapy for thrombosis in the setting
ofCAAincludestheuse ofsingle ordual antiplatelettherapy,
with or without the addition of antivitamin K therapy.
Use of antiplatelet or anticoagulation therapy in patients
with CAAs is based on anecdotal reports. Percutaneous
strategies include coil embolization, autologous saphenous
vein-covered stent grafting, polytetraﬂuoroethylene- (PTFE-
)covered stent grafts, and one case report of DES implan-
tation superimposed on a PTFE-covered stent graft [9,
10]. Surgical strategies that have been described include
aneurysm ligation, resection, marsupialization with interpo-
sitiongraft,andcoronaryarterybypasssurgery.Themajority
of the experience regarding the aforementioned strategies
stem from atherosclerosis-induced CAAs. However, spe-
cial consideration needs to be taken when an immune-
inﬂammatory condition is involved. Studies with systemic
inﬂammatory diseases, that is, Takaysu’s arteritis (TA) have
revealed that the weakening of the walls of the aﬀected
vessels, as well as the increased risk of thrombosis, make
invasive procedures problematic and can result in a high rate
of restenosis and immediate elastic recoil [11, 12]. Moreover,
several studies have shown an increased risk of failure of sur-
gical revascularization in patients with TA [13]. Treatment
strategies to improve clinical outcomes in vasculitis patients
withCAAshavemostlybeendescribedinTakayasu’sarteritis,
Kawasaki’s disease, Wegener’s granulomatosis, polyarteritis
nodosa, and giant cell arteritis either as case reports or
reviews [14–16]. However, a rapid progression of coronary
ectasia to an aneurysm has not been previously described
in RA, but has been reported in a patient with Takayasu’s
arteritis [17]. Treatment strategies to improve outcomes in
vasculitis-induced CAA involve the use of immunosuppres-
sive therapy to abate the underlying inﬂammatory process.
The role of catheter-based intervention needs to be further
explored in this particular patient population. It must be
emphasized that there is no consensus on how coronary
lesions related to systemic inﬂammatory diseases should be
treated.
Our patient presented as a case of RA ﬂare-up due to
a lapse in treatment. This not only caused elevation of
inﬂammatory markers and severe synovitis but probably led
to rapid coronary artery aneurysm formation likely due to
vasculitis. In our patient, both traditional risk factors of
atherosclerosis and the immune-inﬂammatory state of RA
likely contributed to chronic coronary artery ectasia. Coro-
nary vessels with ectatic areas are more prone to aneurys-
matic growththannormal vesselsegments. Wepostulatethat
vasculitis superimposed on a chronically weak vessel wall led
to rapid aneurysm formation. The CAApredisposed to stasis
and then thrombus formation. Eventually, an acute throm-
bus superimposed on a chronic one lead to an NSTEMI.
Perhaps, adherence to warfarin may have prevented the
acute coronary event; however, continued expansion of the
aneurysm could have led to potential rupture.
Ourdecision to proceed with percutaneousmanagement
was predicated on the observance of a rapidly expanding
aneurysm that was not present six months previously.
The combination of both atherosclerosis and RA deemed
this aneurysm at high risk for further growth and poten-
tial rupture; therefore, it was decided to proceed with
both coiling and aggressive medical management of RA.
The presence of thrombus in the aneurysm prevented
wiring of the lesion into the distal lumen. Moreover, this
also precluded deployment of a covered stent, throm-
bus aspiration, and other interventional strategies. The
patient was discharged on a medical regimen consisting
of dual antiplatelet therapy, antithrombotic therapy, and
immunosuppressive agents (methotrexate and prednisone).
Data suggest that methotrexate-treated RA patients have
reductions in cardiovascular morbidity and mortality [18].
There are no guideline recommendations for the man-
agement of CAAs due to the limited data; therefore, the
management strategy should be individualized based on
aneurysm size, location, pathophysiology, and patient symp-
toms.
4.Conclusion
Coronary artery aneurysms have a causal association with
RA. The rate of CAA expansion and rupture is unpre-
dictable; therefore, prompt initiation of immunosuppressive
therapy when indicated is crucial. Each patient presents with
unique clinical and angiographic features, so the treatment
strategy that is utilized should be formulated as such. As
the mechanisms underlying the formation and growth of
CAAs are elucidated, guidelines on how to screen and
manage this condition will be forthcoming. Currently, the
challenge remains to diﬀerentiate high-risk CAAs versus
those associated with a benign outcome.4 Cardiology Research and Practice
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